Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

53.35 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

Peloton Isn’t the ONLY Takeover Target. What Companies Could Be Bought Out in 2022? ↗

February 23, 2022

Savvy investors can generate lucrative returns by investing in companies that look like a number of prime takeover targets.

Via InvestorPlace

Why Jim Cramer Believes Sirius XM Is Inexpensive ↗

February 23, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said CRISPR Therapeutics AG (NASDAQ:

Via Benzinga

What Are Whales Doing With CRISPR Therapeutics ↗

February 22, 2022

A whale with a lot of money to spend has taken a noticeably bullish stance on CRISPR Therapeutics. Looking at options history for CRISPR Therapeutics (NASDAQ:CRSP) we detected 15 strange trades.

Via Benzinga

CRISPR Therapeutics's Return On Capital Employed Insights ↗

February 16, 2022

Benzinga Pro data, CRISPR Therapeutics (NASDAQ:CRSP) reported Q4 sales of $12.90 million. Earnings fell to a loss of $141.25 million, resulting in a 11.09% decrease from last quarter.

Via Benzinga

Week In Review: Xbiome Acquires Diabetic Foot Ulcer Therapy In $139 Million Deal ↗

January 29, 2022

Xbiome, a Shenzhen AI-based microbiome drug development company, in-licensed China rights to an inflammatory disease therapy developed by Aurealis, a Swiss synthetic biology company, in a deal worth up...

Via Talk Markets

Here's How Much You Would Have Made Owning CRISPR Therapeutics Stock In The Last 5 Years ↗

January 25, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 14.31% on an annualized basis. Buying $1,000 In CRSP: 5 years ago, an investor could have...

Via Benzinga

Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review ↗

January 14, 2022

A rebound from Monday's lows faded, with the key indexes all down for the week.

Via Investor's Business Daily

The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks ↗

January 13, 2022

Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year?

Via Investor's Business Daily

3 Deep Value Moonshots to Ride Out Powell’s Taper Tantrum ↗

January 10, 2022

These three companies might seem like zombies compared to other investing opportunities, but they'll be robust during the Fed taper.

Via InvestorPlace

Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics ↗

January 10, 2022

The companies hope to cure diseases of the liver, muscle and central nervous system.

Via Investor's Business Daily

7 Stock Bargains Worth a Look After the Most Recent Pullback ↗

December 27, 2021

Value investors may choose to buy stocks that are out of favor and from among beaten up stock bargains in a variety of sectors.

Via InvestorPlace

Top 5 Moonshots for 2022 Countdown: My No. 5 Pick ↗

December 22, 2021

2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year.

Via InvestorPlace

Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot ↗

December 22, 2021

The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022.

Via Talk Markets

10 Bargain Stocks to Buy After Falling 30% in 2021 ↗

December 20, 2021

If you’re looking for bargain stocks to buy that are down 30% or more in 2021, that’s not an easy task. Here are 10 that fit the bill.

Via InvestorPlace

Biotech Playbook 2021: No Help From Small Caps In Q4 ↗

December 14, 2021

Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but...

Via Talk Markets

Adobe Earnings Strangle Trade ↗

December 11, 2021

Adobe announces earnings this week, and we plan on using an options strategy called a

Via Talk Markets

CRISPR Therapeutics Is One of Today’s Best Biotech Value Investments ↗

December 09, 2021

Don't let the downtrend in CRSP stock fool you; the company is still making headway in advancing potentially life-changing therapeutics.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021 ↗

December 07, 2021

Upgrades For CarMax Inc (NYSE:

Via Benzinga

Why CRISPR Therapeutics Stock Sank 12.5% in November ↗

December 05, 2021

The gene-editing specialist's share price is now down roughly 54% in 2021.

Via The Motley Fool

Jim Cramer Shares His Thoughts On Chegg, Bristol-Myers Squibb And More ↗

November 30, 2021

On CNBC’s "Mad Money Lightning Round," Jim Cramer said with Matterport, Inc. (NASDAQ:

Via Benzinga

Biotech Stocks are Due for a Rally ↗

November 22, 2021

There are many rebalancing trades left in your stock portfolio but biotech is in the doldrums.

Via Talk Markets

Do CRISPR Therapeutics and Intellia Face a Big Safety Risk? ↗

November 21, 2021

CRISPR gene editing is promising, but there's a risk that it can cause unwanted mutations.

Via The Motley Fool

Better Buy: Vertex Pharmaceuticals vs. CRISPR ↗

November 20, 2021

The companies are collaborating on a potential blockbuster.

Via The Motley Fool

Looking for Growth in Small and Mid Cap Life Science Stocks ↗

November 15, 2021

2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps.

Via Talk Markets

Being First Is Not Enough For Crispr Therapeutics ↗

November 15, 2021

CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies.

Via InvestorPlace

Why CRISPR Therapeutics Stock Fell 18.4% in October ↗

November 04, 2021

The gene-editing specialist's stock is now down roughly 37% year to date.

Via The Motley Fool

Why Vertex Is Striking Another Gene-Editing Deal With a Company Not Named CRISPR Therapeutics ↗

November 04, 2021

Vertex plans to develop gene-editing therapies with Mammoth Biosciences.

Via The Motley Fool

3 Things About CRISPR Therapeutics That Smart Investors Know ↗

October 20, 2021

The company's value isn't reflected in typical performance metrics.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021 ↗

October 19, 2021

Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ:

Via Benzinga

2 Gene-Editing Stocks to Have on Your Radar Right Now ↗

October 17, 2021

They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies.

Via The Motley Fool

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.